Protocol Page


	Study ID (Protocol Number)
	CA215-001


	STUDY LOCATIONS*
	Local Institution New York, NY 10029 Not yet recruiting	University Of Texas M.D. Anderson Cancer Center Houston, TX 77030 Recruiting
	Mayo Clinic Rochester, MN 55905 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Multiple Ascending Dose of BMS-911543
	STUDY OVERVIEW
	The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum Tolerated Dose or at a Clinically Active Dose, and to determine if BMS-911543 will demonstrate efficacy in symptomatic myelofibrosis.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.